NO325484B1 - 2-arylimino-2,3-dihydrotiazolderivater og anvendelse derav samt medikament og farmasoytisk sammensetning - Google Patents

2-arylimino-2,3-dihydrotiazolderivater og anvendelse derav samt medikament og farmasoytisk sammensetning Download PDF

Info

Publication number: NO325484B1
Authority: NO; Norway
Prior art keywords: rest; remainder; syndrome; resin; diseases
Prior art date: 2001-01-12

Application number

NO20033120A

Other languages

English (en)

Norwegian (no)

Other versions

NO20033120L (no

NO20033120D0 (no

Inventor

Carole Sackur

Christophe Moinet

Christophe Thurieau

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-12

Filing date

2003-07-08

Publication date

2008-05-13

2003-07-08 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2003-07-08 Publication of NO20033120D0 publication Critical patent/NO20033120D0/no

2003-09-11 Publication of NO20033120L publication Critical patent/NO20033120L/no

2008-05-13 Publication of NO325484B1 publication Critical patent/NO325484B1/no

Links

229940079593 drug Drugs 0.000 title claims description 12
239000003814 drug Substances 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 46
206010016654 Fibrosis Diseases 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
230000004761 fibrosis Effects 0.000 claims description 21
201000010099 disease Diseases 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
206010012735 Diarrhoea Diseases 0.000 claims description 16
230000001575 pathological effect Effects 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 13
208000032843 Hemorrhage Diseases 0.000 claims description 12
208000034158 bleeding Diseases 0.000 claims description 12
230000000740 bleeding effect Effects 0.000 claims description 12
108050001286 Somatostatin Receptor Proteins 0.000 claims description 11
102000011096 Somatostatin receptor Human genes 0.000 claims description 11
238000002512 chemotherapy Methods 0.000 claims description 9
230000005764 inhibitory process Effects 0.000 claims description 9
206010000599 Acromegaly Diseases 0.000 claims description 8
230000003111 delayed effect Effects 0.000 claims description 8
208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 7
238000011161 development Methods 0.000 claims description 7
230000002124 endocrine Effects 0.000 claims description 7
208000030304 gastrointestinal bleeding Diseases 0.000 claims description 7
206010007270 Carcinoid syndrome Diseases 0.000 claims description 6
208000008589 Obesity Diseases 0.000 claims description 6
208000007913 Pituitary Neoplasms Diseases 0.000 claims description 6
230000001684 chronic effect Effects 0.000 claims description 6
201000000052 gastrinoma Diseases 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
208000011580 syndromic disease Diseases 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 5
208000030507 AIDS Diseases 0.000 claims description 4
208000008279 Dumping Syndrome Diseases 0.000 claims description 4
206010033645 Pancreatitis Diseases 0.000 claims description 4
208000008469 Peptic Ulcer Diseases 0.000 claims description 4
208000032395 Post gastric surgery syndrome Diseases 0.000 claims description 4
208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
201000002510 thyroid cancer Diseases 0.000 claims description 4
208000003200 Adenoma Diseases 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 3
206010059245 Angiopathy Diseases 0.000 claims description 3
206010003445 Ascites Diseases 0.000 claims description 3
208000023328 Basedow disease Diseases 0.000 claims description 3
206010006187 Breast cancer Diseases 0.000 claims description 3
208000026310 Breast neoplasm Diseases 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
206010052097 Dawn phenomenon Diseases 0.000 claims description 3
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
102000004862 Gastrin releasing peptide Human genes 0.000 claims description 3
108090001053 Gastrin releasing peptide Proteins 0.000 claims description 3
206010018265 Gigantism Diseases 0.000 claims description 3
206010018404 Glucagonoma Diseases 0.000 claims description 3
208000015023 Graves' disease Diseases 0.000 claims description 3
208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
206010020850 Hyperthyroidism Diseases 0.000 claims description 3
208000001953 Hypotension Diseases 0.000 claims description 3
208000009164 Islet Cell Adenoma Diseases 0.000 claims description 3
206010029748 Noonan syndrome Diseases 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
208000002193 Pain Diseases 0.000 claims description 3
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
206010033635 Pancreatic pseudocyst Diseases 0.000 claims description 3
206010033664 Panic attack Diseases 0.000 claims description 3
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims description 3
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims description 3
206010036832 Prolactinoma Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
208000001647 Renal Insufficiency Diseases 0.000 claims description 3
206010039710 Scleroderma Diseases 0.000 claims description 3
201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
206010042953 Systemic sclerosis Diseases 0.000 claims description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
208000025865 Ulcer Diseases 0.000 claims description 3
208000009311 VIPoma Diseases 0.000 claims description 3
201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
238000002399 angioplasty Methods 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
230000001925 catabolic effect Effects 0.000 claims description 3
210000003169 central nervous system Anatomy 0.000 claims description 3
230000007882 cirrhosis Effects 0.000 claims description 3
208000019425 cirrhosis of liver Diseases 0.000 claims description 3
208000033679 diabetic kidney disease Diseases 0.000 claims description 3
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 3
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 3
231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 3
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 3
239000003862 glucocorticoid Substances 0.000 claims description 3
201000008980 hyperinsulinism Diseases 0.000 claims description 3
230000036543 hypotension Effects 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
206010022498 insulinoma Diseases 0.000 claims description 3
230000000968 intestinal effect Effects 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
210000004185 liver Anatomy 0.000 claims description 3
210000004072 lung Anatomy 0.000 claims description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
206010027191 meningioma Diseases 0.000 claims description 3
201000002528 pancreatic cancer Diseases 0.000 claims description 3
208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
208000021255 pancreatic insulinoma Diseases 0.000 claims description 3
208000019906 panic disease Diseases 0.000 claims description 3
230000007170 pathology Effects 0.000 claims description 3
201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
208000007232 portal hypertension Diseases 0.000 claims description 3
238000010992 reflux Methods 0.000 claims description 3
230000037390 scarring Effects 0.000 claims description 3
201000009881 secretory diarrhea Diseases 0.000 claims description 3
201000002859 sleep apnea Diseases 0.000 claims description 3
229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
231100000397 ulcer Toxicity 0.000 claims description 3
206010012559 Developmental delay Diseases 0.000 claims description 2
208000000624 Esophageal and Gastric Varices Diseases 0.000 claims description 2
208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 2
206010072610 Skeletal dysplasia Diseases 0.000 claims description 2
206010056091 Varices oesophageal Diseases 0.000 claims description 2
206010046996 Varicose vein Diseases 0.000 claims description 2
208000024170 esophageal varices Diseases 0.000 claims description 2
201000010120 esophageal varix Diseases 0.000 claims description 2
201000006370 kidney failure Diseases 0.000 claims description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 2
208000027185 varicose disease Diseases 0.000 claims description 2
210000000813 small intestine Anatomy 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 219
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 207
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
239000011347 resin Substances 0.000 description 76
229920005989 resin Polymers 0.000 description 76
238000000034 method Methods 0.000 description 53
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 35
239000000203 mixture Substances 0.000 description 31
-1 pamoate Chemical compound 0.000 description 30
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
239000002904 solvent Substances 0.000 description 23
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 19
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
229960000553 somatostatin Drugs 0.000 description 18
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 17
238000011068 loading method Methods 0.000 description 16
238000002360 preparation method Methods 0.000 description 16
239000003875 Wang resin Substances 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
239000007787 solid Substances 0.000 description 13
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
238000005481 NMR spectroscopy Methods 0.000 description 12
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 12
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 12
238000012360 testing method Methods 0.000 description 12
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 11
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 11
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 11
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 11
150000004985 diamines Chemical class 0.000 description 10
239000012634 fragment Substances 0.000 description 10
235000017557 sodium bicarbonate Nutrition 0.000 description 10
229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
239000000243 solution Substances 0.000 description 10
102000005157 Somatostatin Human genes 0.000 description 9
108010056088 Somatostatin Proteins 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
230000002378 acidificating effect Effects 0.000 description 8
238000013019 agitation Methods 0.000 description 8
239000000010 aprotic solvent Substances 0.000 description 8
238000000605 extraction Methods 0.000 description 8
239000012458 free base Substances 0.000 description 8
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
239000000047 product Substances 0.000 description 8
239000012047 saturated solution Substances 0.000 description 8
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 7
238000010828 elution Methods 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
239000012980 RPMI-1640 medium Substances 0.000 description 6
239000001506 calcium phosphate Substances 0.000 description 6
229910000389 calcium phosphate Inorganic materials 0.000 description 6
235000011010 calcium phosphates Nutrition 0.000 description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
238000000921 elemental analysis Methods 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
238000001914 filtration Methods 0.000 description 6
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
101000632994 Homo sapiens Somatostatin Proteins 0.000 description 5
RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
238000000975 co-precipitation Methods 0.000 description 5
102000045305 human SST Human genes 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000001890 transfection Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
108010051696 Growth Hormone Proteins 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
102100038803 Somatotropin Human genes 0.000 description 4
239000002585 base Substances 0.000 description 4
230000027455 binding Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
239000007822 coupling agent Substances 0.000 description 4
239000003480 eluent Substances 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
239000000122 growth hormone Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
FLAYZKKEOIAALB-UHFFFAOYSA-N 2-bromo-1-(4-chlorophenyl)ethanone Chemical compound ClC1=CC=C(C(=O)CBr)C=C1 FLAYZKKEOIAALB-UHFFFAOYSA-N 0.000 description 3
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
244000309464 bull Species 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
125000001841 imino group Chemical group [H]N=* 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Substances ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 3
239000008188 pellet Substances 0.000 description 3
238000005897 peptide coupling reaction Methods 0.000 description 3
239000012429 reaction media Substances 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
101150084577 SST2 gene Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229940117953 phenylisothiocyanate Drugs 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
UIRPOZKMSMHJBQ-KXPSTEIISA-N pubchem11605 Chemical compound OC(=O)C(F)(F)F.C([C@H]1OB(O[C@]11C)[C@@H](N)C)[C@H]2C(C)(C)[C@@H]1C2 UIRPOZKMSMHJBQ-KXPSTEIISA-N 0.000 description 2
230000028327 secretion Effects 0.000 description 2
108010064556 somatostatin receptor subtype-4 Proteins 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000013598 vector Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
NVRNCBWTEDOAQA-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)-2-bromoethanone Chemical compound C1=CC=C2OC(C(=O)CBr)=CC2=C1 NVRNCBWTEDOAQA-UHFFFAOYSA-N 0.000 description 1
YUTFQTAITWWGFH-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2OC(C(=O)C)=CC2=C1 YUTFQTAITWWGFH-UHFFFAOYSA-N 0.000 description 1
LFDPCVMXSXYDQA-UHFFFAOYSA-N 1-ethenylpyridin-1-ium;hydrobromide Chemical compound Br.C=C[N+]1=CC=CC=C1 LFDPCVMXSXYDQA-UHFFFAOYSA-N 0.000 description 1
JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 1
AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 1
XTLWRKHVOFEQQU-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole-4-carboxamide Chemical class NC(=O)C1=CSCN1 XTLWRKHVOFEQQU-UHFFFAOYSA-N 0.000 description 1
PTPZBCHKQSHXQZ-UHFFFAOYSA-N 2-(4-bromo-3-oxobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(=O)CBr)C(=O)C2=C1 PTPZBCHKQSHXQZ-UHFFFAOYSA-N 0.000 description 1
NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
BSBAIUKITMNFCT-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenylimino-1,3-thiazol-3-yl]ethanamine Chemical compound NCCN1C(C=2C=CC(Cl)=CC=2)=CSC1=NC1=CC=CC=C1 BSBAIUKITMNFCT-UHFFFAOYSA-N 0.000 description 1
FZLFRKVMNDVUMD-UHFFFAOYSA-N 2-[4-[[4-(4-chlorophenyl)-3-(2-phenylethyl)-1,3-thiazol-2-ylidene]amino]phenyl]ethanamine Chemical compound C1=CC(CCN)=CC=C1N=C1N(CCC=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=CS1 FZLFRKVMNDVUMD-UHFFFAOYSA-N 0.000 description 1
YSNYFPFEBBRSHS-UHFFFAOYSA-N 2-amino-1,3-thiazole-4-carboxamide Chemical class NC(=O)C1=CSC(N)=N1 YSNYFPFEBBRSHS-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
DUKKFOANRCPHFB-UHFFFAOYSA-N 3-(4-aminobutyl)-n-benzhydryl-2-(4-bromophenyl)imino-1,3-thiazole-4-carboxamide Chemical compound NCCCCN1C(C(=O)NC(C=2C=CC=CC=2)C=2C=CC=CC=2)=CSC1=NC1=CC=C(Br)C=C1 DUKKFOANRCPHFB-UHFFFAOYSA-N 0.000 description 1
PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
LNPMZQXEPNWCMG-UHFFFAOYSA-N 4-(2-aminoethyl)aniline Chemical compound NCCC1=CC=C(N)C=C1 LNPMZQXEPNWCMG-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ORXCBXIQZKCNND-GNVQSUKOSA-N C=1S\C(=N/C=2C3=CC=CC=C3C=CC=2)N(CC(=O)NCCCCN)C=1C1=CC=C(Cl)C=C1 Chemical compound C=1S\C(=N/C=2C3=CC=CC=C3C=CC=2)N(CC(=O)NCCCCN)C=1C1=CC=C(Cl)C=C1 ORXCBXIQZKCNND-GNVQSUKOSA-N 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
239000007821 HATU Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
206010038934 Retinopathy proliferative Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(II) bromide Substances [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000003890 fistula Effects 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229940127264 non-peptide agonist Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000003431 oxalo group Chemical group 0.000 description 1
201000011116 pancreatic cholera Diseases 0.000 description 1
MYDQAEQZZKVJSL-UHFFFAOYSA-N pentyl carbamate Chemical compound CCCCCOC(N)=O MYDQAEQZZKVJSL-UHFFFAOYSA-N 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
DPLOGSUBQDREOU-UHFFFAOYSA-N tert-butyl n-(5-aminopentyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCN DPLOGSUBQDREOU-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
SFLXUZPXEWWQNH-UHFFFAOYSA-K tetrabutylazanium;tribromide Chemical compound [Br-].[Br-].[Br-].CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC SFLXUZPXEWWQNH-UHFFFAOYSA-K 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Developing Agents For Electrophotography (AREA)
Liquid Crystal (AREA)
Thin Film Transistor (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20033120A 2001-01-12 2003-07-08 2-arylimino-2,3-dihydrotiazolderivater og anvendelse derav samt medikament og farmasoytisk sammensetning NO325484B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0100396A FR2819508B1 (fr)	2001-01-12	2001-01-12	Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
PCT/FR2002/000093 WO2002055510A1 (fr)	2001-01-12	2002-01-11	Derives de 2-arylimino-2,3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Publications (3)

Publication Number	Publication Date
NO20033120D0 NO20033120D0 (no)	2003-07-08
NO20033120L NO20033120L (no)	2003-09-11
NO325484B1 true NO325484B1 (no)	2008-05-13

Family

ID=8858747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033120A NO325484B1 (no)	2001-01-12	2003-07-08	2-arylimino-2,3-dihydrotiazolderivater og anvendelse derav samt medikament og farmasoytisk sammensetning

Country Status (26)

Country	Link
US (1)	US7220765B2 (cs)
EP (1)	EP1353912B1 (cs)
JP (1)	JP4452443B2 (cs)
KR (1)	KR100874298B1 (cs)
CN (1)	CN100534988C (cs)
AR (1)	AR035730A1 (cs)
AT (1)	ATE302765T1 (cs)
AU (1)	AU2002233407B2 (cs)
BR (1)	BR0206407A (cs)
CA (1)	CA2434203C (cs)
CZ (1)	CZ20031917A3 (cs)
DE (1)	DE60205717T2 (cs)
DK (1)	DK1353912T3 (cs)
ES (1)	ES2248514T3 (cs)
FR (1)	FR2819508B1 (cs)
HU (1)	HUP0500958A3 (cs)
IL (2)	IL156647A0 (cs)
IS (1)	IS2331B (cs)
MX (1)	MXPA03006249A (cs)
MY (1)	MY142762A (cs)
NO (1)	NO325484B1 (cs)
NZ (1)	NZ526692A (cs)
PL (1)	PL367627A1 (cs)
RU (1)	RU2283838C2 (cs)
WO (1)	WO2002055510A1 (cs)
ZA (1)	ZA200305100B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7534887B2 (en)	2003-09-30	2009-05-19	Takeda Pharmaceutical Company Limited	Thiazoline derivative and use of the same
JP4896387B2 (ja) *	2003-09-30	2012-03-14	武田薬品工業株式会社	チアゾリン誘導体およびその用途
US7999137B2 (en) *	2005-09-13	2011-08-16	Bayer Cropscience Ag	Pesticide bi-phenyl-amidine derivatives
KR100863239B1 (ko) *	2007-05-23	2008-10-15	한국과학기술연구원	신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
WO2009157415A1 (ja) *	2008-06-23	2009-12-30	東ソー株式会社	蛋白質精製用分離剤及び蛋白質精製方法
KR101049935B1 (ko)	2008-12-03	2011-07-15	한국과학기술연구원	신규한 티아졸린계 화합물 및 이를 포함하는 ｔ-형 칼슘 채널 저해제
ES2351569B8 (es) *	2009-05-07	2012-06-20	Bcn Peptides S.A.	Ligandos peptídicos de receptores de somatostatina.
EP2604606B1 (en) *	2010-08-09	2014-10-08	Pharmadesign, Inc.	Inhibitor of casein kinase 1delta and casein kinase 1epsilon
RU2521390C1 (ru) *	2013-03-14	2014-06-27	Общество с ограниченной ответственностью "Тиацен"	Производное роданина и средство для профилактики опухолевых заболеваний
JP6894498B2 (ja)	2016-08-12	2021-06-30	ザカトリックユニバーシティオブコリアインダストリー−アカデミックコーオペレイションファウンデーション	軟組織硬化用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1347371A (fr) *	1962-01-19	1963-12-27	Ciba Geigy	Agents de lutte contre les organismes nuisibles, renfermant des thiazolines, à usages agricoles et industriels
BE627278A (cs) *	1962-01-19
DE2926771A1 (de) *	1979-07-03	1981-01-15	Hoechst Ag	Thiazolidinderivate und verfahren zu ihrer herstellung
DE3049460A1 (de) *	1980-12-30	1982-07-29	Hoechst Ag, 6000 Frankfurt	"thiazolinderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
FR2735777B1 (fr) *	1995-06-21	1997-09-12	Sanofi Sa	Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2796643B1 (fr) *	1999-07-22	2005-04-29	Sod Conseils Rech Applic	Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

2001
- 2001-01-12 FR FR0100396A patent/FR2819508B1/fr not_active Expired - Fee Related
- 2001-12-27 MY MYPI20015897A patent/MY142762A/en unknown
2002
- 2002-01-11 DK DK02700318T patent/DK1353912T3/da active
- 2002-01-11 JP JP2002556180A patent/JP4452443B2/ja not_active Expired - Fee Related
- 2002-01-11 CA CA2434203A patent/CA2434203C/fr not_active Expired - Fee Related
- 2002-01-11 KR KR1020037009303A patent/KR100874298B1/ko not_active Expired - Fee Related
- 2002-01-11 AU AU2002233407A patent/AU2002233407B2/en not_active Ceased
- 2002-01-11 NZ NZ526692A patent/NZ526692A/en unknown
- 2002-01-11 ES ES02700318T patent/ES2248514T3/es not_active Expired - Lifetime
- 2002-01-11 BR BR0206407-3A patent/BR0206407A/pt not_active IP Right Cessation
- 2002-01-11 AT AT02700318T patent/ATE302765T1/de not_active IP Right Cessation
- 2002-01-11 CN CNB02803662XA patent/CN100534988C/zh not_active Expired - Fee Related
- 2002-01-11 EP EP02700318A patent/EP1353912B1/fr not_active Expired - Lifetime
- 2002-01-11 WO PCT/FR2002/000093 patent/WO2002055510A1/fr not_active Ceased
- 2002-01-11 IL IL15664702A patent/IL156647A0/xx unknown
- 2002-01-11 AR ARP020100094A patent/AR035730A1/es unknown
- 2002-01-11 PL PL02367627A patent/PL367627A1/xx not_active Application Discontinuation
- 2002-01-11 DE DE60205717T patent/DE60205717T2/de not_active Expired - Lifetime
- 2002-01-11 HU HU0500958A patent/HUP0500958A3/hu unknown
- 2002-01-11 CZ CZ20031917A patent/CZ20031917A3/cs unknown
- 2002-01-11 MX MXPA03006249A patent/MXPA03006249A/es active IP Right Grant
- 2002-01-11 RU RU2003124749/04A patent/RU2283838C2/ru not_active IP Right Cessation
2003
- 2003-06-25 IL IL156647A patent/IL156647A/en not_active IP Right Cessation
- 2003-06-30 ZA ZA200305100A patent/ZA200305100B/en unknown
- 2003-07-08 NO NO20033120A patent/NO325484B1/no not_active IP Right Cessation
- 2003-07-08 US US10/615,481 patent/US7220765B2/en not_active Expired - Fee Related
- 2003-07-09 IS IS6870A patent/IS2331B/is unknown

Also Published As

Publication number	Publication date
RU2003124749A (ru)	2005-01-10
NO20033120L (no)	2003-09-11
HUP0500958A3 (en)	2009-12-28
HUP0500958A2 (en)	2006-01-30
EP1353912B1 (fr)	2005-08-24
PL367627A1 (en)	2005-03-07
NO20033120D0 (no)	2003-07-08
FR2819508B1 (fr)	2005-01-21
CZ20031917A3 (cs)	2004-05-12
KR20040038905A (ko)	2004-05-08
JP2004530643A (ja)	2004-10-07
AR035730A1 (es)	2004-07-07
KR100874298B1 (ko)	2008-12-18
RU2283838C2 (ru)	2006-09-20
CA2434203C (fr)	2010-12-07
NZ526692A (en)	2006-04-28
EP1353912A1 (fr)	2003-10-22
ES2248514T3 (es)	2006-03-16
CN100534988C (zh)	2009-09-02
WO2002055510A1 (fr)	2002-07-18
DE60205717T2 (de)	2006-06-22
IL156647A0 (en)	2004-01-04
DE60205717D1 (de)	2005-09-29
CA2434203A1 (fr)	2002-07-18
BR0206407A (pt)	2004-01-06
DK1353912T3 (da)	2006-01-09
MY142762A (en)	2010-12-31
ATE302765T1 (de)	2005-09-15
ZA200305100B (en)	2004-08-27
IS2331B (is)	2008-02-15
CN1871224A (zh)	2006-11-29
US7220765B2 (en)	2007-05-22
US20070043095A1 (en)	2007-02-22
IS6870A (is)	2003-07-09
MXPA03006249A (es)	2003-09-22
FR2819508A1 (fr)	2002-07-19
AU2002233407B2 (en)	2006-11-23
JP4452443B2 (ja)	2010-04-21
IL156647A (en)	2009-07-20

Legal Events

Date	Code	Title	Description
2011-09-05	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6727269B1 (en)	2004-04-27	2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
CN100569770C (zh)	2009-12-16	5-苯基噻唑衍生物和它们作为pi3激酶抑制剂的用途
US7423052B2 (en)	2008-09-09	Piperidine compounds for use as orexin receptor antagoinst
US7468367B2 (en)	2008-12-23	Ethylene diamine derivatives and their use as orexin-receptor antagonists
US20030191164A1 (en)	2003-10-09	Propane-1,3-dione derivatives
WO2002044172A1 (en)	2002-06-06	Morpholine derivatives as antagonists of orexin receptors
JP2004518613A (ja)	2004-06-24	イミダゾリル誘導体
RU2283838C2 (ru)	2006-09-20	Производные 2-арилимино-2,3-дигидротиазолов, способы их получения и их терапевтическое применение
HK1048314B (en)	2009-08-21	2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands